Staying The Course: PhRMA Announces ‘Pro-Consumer’ Reform Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Recently installed CEO Stephen Ubl presents policy solutions as industry’s best response to ongoing public criticism over high drug prices.
You may also be interested in...
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
CMS-Manufacturer Discussion Of Medicare Price Negotiation Program Scheduled For 13 December
Agency reaches out to manufacturers as it develops its approach to implementing the controversial new program.
Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.